Skip to main content

Florian Ringel

Surgical Treatment of Diseases of the Brain

Portrait of Florian Ringel
Florian Ringel

Research website

Positions held

  • Since 2016: Chairman, Head of Neurosurgery, University Medical Center (UMC), Mainz
  • 2006 - 2016: Leitender Oberarzt, Department of Neurosurgery, Technical University of Munich

Education

  • 2009: Habilitation, Department of Neurosurgery, Klinikum Rechts der Isar, Technical University of Munich
  • 2006: Board specialisation in Neurosurgery, Klinikum Rechts der Isar, Technical University of Munich
  • 2004: Doctoral thesis: „Die Azidose-induzierte Schwellung und intrazelluläre Azidose von Gliazellen – Bedeutung von Anionen und Kalzium“ 
  • 1991 - 1998: Medical school, Ludwig Maximilan University, Munich

Selected publications by Florian Ringel

Anetsberger A, Gempt J, Blobner M, Ringel F, Bogdanski R, Heim M, Schneider G, Meyer B, Schmid S, Ryang YM, Wostrack M, Schneider J, Martin J, Ehrhardt M and Jungwirth B (2020) Impact of goal-directed therapy on delayed ischemia after aneurysmal subarachnoid hemorrhage. Stroke, 51:2287–2296 Link

Keric N, Kalasauskas D, Freyschlag CF, Gempt J, Misch M, Poplawski A, Lange N, Ayyad A, Thomé C, Vajkoczy P, Meyer B and Ringel F (2020) Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas. J Neuro Oncol, 146:347–355 Link

Kim EL, Sorokin M, Kantelhardt SR, Kalasauskas D, Sprang B, Fauss J, Ringel F, Garazha A, Albert E, Gaifullin N, Hartmann C, Naumann N, Bikar SE, Giese A and Buzdin A (2020) Intratumoral heterogeneity and longitudinal changes in gene expression predict differential drug sensitivity in newly diagnosed and recurrent glioblastoma. Cancers, 12:520 Link

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C and Glas M (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. Lancet, 393:678–688 Link

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M and Herrlinger U (2018) Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-Oncology, 20:975–985 Link